Micro RNA Expression after Ingestion of Fucoidan; A Clinical Study.
clinical
fucoidan
microRNA, anti-inflammatory, anti-cancer
Journal
Marine drugs
ISSN: 1660-3397
Titre abrégé: Mar Drugs
Pays: Switzerland
ID NLM: 101213729
Informations de publication
Date de publication:
28 Feb 2020
28 Feb 2020
Historique:
received:
11
02
2020
revised:
26
02
2020
accepted:
26
02
2020
entrez:
4
3
2020
pubmed:
4
3
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Fucoidans are a class of fucose-rich sulfated polysaccharides derived from brown macroalgae that exert a range of biological activities in vitro and in vivo. To generate an unbiased assessment of pathways and processes affected by fucoidan, a placebo-controlled double-blind pilot study was performed in healthy volunteers. Blood samples were taken immediately before and 24 h after ingestion of a single dose of 1 g of
Identifiants
pubmed: 32121066
pii: md18030143
doi: 10.3390/md18030143
pmc: PMC7143719
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
MicroRNAs
0
Polysaccharides
0
fucoidan
9072-19-9
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Australian Department of Industry and Innovation (Innovations connections), grant number (RC49508).
ID : RC49508
Références
Cell Metab. 2019 Oct 1;30(4):656-673
pubmed: 31447320
J Med Food. 2014 Jul;17(7):830-2
pubmed: 24611906
Sci Rep. 2016 Oct 24;6:35855
pubmed: 27775051
J Food Sci. 2011 Apr;76(3):T77-83
pubmed: 21535865
PLoS One. 2016 Mar 21;11(3):e0151771
pubmed: 26998997
Mol Med Rep. 2018 May;17(5):7089-7096
pubmed: 29568947
Biopharm Drug Dispos. 2018 Jun;39(6):298-307
pubmed: 29904925
J Nat Med. 2013 Jul;67(3):534-44
pubmed: 23090005
Mar Drugs. 2016 Jul 07;14(7):
pubmed: 27399727
Cell Mol Immunol. 2014 May;11(3):263-74
pubmed: 24561457
Biomol Ther (Seoul). 2017 May 1;25(3):272-278
pubmed: 27871155
Chin J Integr Med. 2011 Aug 18;:
pubmed: 21853347
Anticancer Res. 2005 May-Jun;25(3B):2129-33
pubmed: 16158954
J Altern Complement Med. 2019 Mar;25(3):346-352
pubmed: 30312135
Biochem J. 1961 Feb;78:312-9
pubmed: 13723349
J Pharm Pharmacol. 2012 Apr;64(4):604-9
pubmed: 22420666
Mar Drugs. 2019 Oct 09;17(10):
pubmed: 31601041
Mar Drugs. 2013 Aug 19;11(8):2982-99
pubmed: 23966032
Mar Drugs. 2014 May 30;12(6):3292-306
pubmed: 24886867
Mar Drugs. 2019 Jan 14;17(1):
pubmed: 30646537
Mar Drugs. 2019 Jan 07;17(1):
pubmed: 30621045
Evid Based Complement Alternat Med. 2018 Jun 12;2018:8109621
pubmed: 30008787
Nutr Res. 2019 May;65:54-62
pubmed: 30952503
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Adv Nutr. 2017 Jan 17;8(1):105-112
pubmed: 28096131
Sci Rep. 2017 Jan 17;7:40760
pubmed: 28094330
Mar Drugs. 2015 Sep 24;13(10):6099-116
pubmed: 26404322
Oncotarget. 2017 Mar 14;8(11):17887-17896
pubmed: 28060735
Glycobiology. 2014 Dec;24(12):1265-74
pubmed: 24973252
Mar Drugs. 2018 Sep 18;16(9):
pubmed: 30231464
J Cell Physiol. 2016 Mar;231(3):688-97
pubmed: 26241708
J Cancer. 2016 Dec 9;7(15):2408-2419
pubmed: 27994679
J Nutr Biochem. 2010 Aug;21(8):671-9
pubmed: 19576750
Macromol Biosci. 2018 Oct;18(10):e1800137
pubmed: 30113760
BMC Complement Altern Med. 2016 May 28;16:151
pubmed: 27234961
Anal Biochem. 1991 Aug 15;197(1):157-62
pubmed: 1952059
Mol Carcinog. 2010 Aug;49(8):771-82
pubmed: 20572161